Related Experiment Video
Updated: Feb 27, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Management of iron overload in hemoglobinopathies
S Allali1, M de Montalembert1, V Brousse1
1Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants malades hospital, AP-HP, Paris Descartes University, 149, rue de Sèvres, 75015 Paris, France; Laboratory of Excellence GR-ex, 75015 Paris, France; Pediatric Reference Center for Sickle cell Disease, 75015 Paris, France.
Iron overload from blood transfusions is a serious complication of hemoglobinopathies like thalassemia and sickle cell disease. Monitoring and chelation therapy are crucial for managing organ damage in these patients.
Area of Science:
- Hematology
- Internal Medicine
- Pharmacology
Background:
- Hemoglobinopathies, including thalassemia and sickle cell disease, are common monogenic disorders.
- Blood transfusions improve prognosis but lead to iron overload, causing multi-organ damage.
- Ineffective erythropoiesis in thalassemia exacerbates iron overload by increasing intestinal absorption.
Purpose of the Study:
- To review the characteristics and indications of iron chelators used in managing transfusion-related iron overload.
- To highlight the importance of monitoring iron levels in chronically transfused patients.
Main Methods:
- Review of current literature on iron overload in hemoglobinopathies.
- Discussion of diagnostic tools such as Magnetic Resonance Imaging (MRI) for myocardial T2* and Liver Iron Content (LIC).
- Overview of available iron chelating agents: deferoxamine, deferiprone, and deferasirox.
Main Results:
- Transfusion-related cardiac iron overload is a leading cause of death in thalassemia.
- Hepatic damage is a significant concern in sickle cell disease due to iron overload.
- Regular monitoring and chelation therapy are essential for mitigating organ damage.
Conclusions:
- Effective management of iron overload is critical for improving outcomes in patients with hemoglobinopathies.
- Available iron chelators offer different administration routes and profiles, requiring careful consideration of patient needs.
- Continued research and development in iron chelation therapy are necessary.
Related Concept Videos
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Lifecycle of Erythrocytes
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
The Early Endosome: Endocytosis of Transferrin

